Back to Posts

Back to Posts

May 3, 2022 Company News

ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook

A Customer-Centric Approach to Clinical Research Solutions

ProPharma Group Named a Top CRO of 2022ProPharma Group is honored to be named Top 10 CRO 2022 by Pharma Tech Outlook magazine.

Pharma Tech Outlook’s 5th annual listing of the Top 10 CROs of 2022 showcases 10 companies that are at the forefront of providing CRO services and transforming businesses.

ProPharma Group brings a customer-centric approach to clinical research solutions, leveraging our team’s experience to design the right clinical trial solution that enhances clinical trial outcomes.

“From the get-go, ProPharma Group aims to be an extension of the client’s internal team. We believe that not everything is one size fits all, our service is more fit for purpose.”
Brittany Strubbe, Vice President of Business Development, Clinical Research Solutions

ProPharma Group’s suite of services can support customers throughout the entire lifecycle of their products and therapies. Once products are on the market, the post-marketing safety and medical information teams can continue to provide support.

At ProPharma Group, we stand by our goal of improving patient health and safety while doing right by our sponsors. We adopt an innovative, collaborative, and forward-looking approach versus a responsive and reactive one.

Our clients choose ProPharma Group because we are nimble, flexible, and truly care about helping them achieve their goals.

Click here to read the full article


Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.

We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.

Interested in gaining an industry edge? Let us help you stay up to date.

All fields are required.
There was a problem with your submission. Errors have been highlighted below.